Clinical TrialsAEMD continues to make progress along the clinical front, receiving its second full ethics approval for its safety, feasibility, and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors.
Financial PerformanceGAAP loss per share of ($0.93) was narrower than consensus of ($1.26) and analysts' estimate of ($1.10).
PartnershipsAnnounces a supply agreement with one of the largest office supply companies in America, Cintas, for SilverSeal products.